Tag: GlobeNewswire

• Updated TUPELO results featured in a Presidential Plenary at CGA-IGC: Lisa Boardman, M.D., Professor of Medicine at Mayo Clinic, presented updated findings from the Phase 1b/2 TUPELO trial in familial adenomatous polyposis (FAP) at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting.
• Deep reductions sustained off treatment: In an expanded adult population aged 18 years and older, after 12 weeks of treatment, patients achieved a 47% median reduction in total polyp burden, with approximately 1 in 3 achieving reductions of ≥65%. Twelve weeks after stopping treatment, 85% of evaluable patients remained below baseline.
• Activity throughout the upper and lower GI tract, including near-clearance: After 12 weeks of treatment, nearly 1 in 2 patients in the upper GI and more than 1 in 3 in the lower GI achieved polyp burden reductions of ≥65%. Two patients achieved ≥98% reductions in upper GI polyp burden.
• Substantial reductions in larger, higher-risk polyps: Six of eight patients with polyps >5 mm at baseline had reductions in the number of these polyps after 12 weeks of treatment. Four achieved reductions of ≥80%, including two whose larger-polyp counts fell from more than 90 polyps to one.   
• No new safety signals observed: Favorable chronic dosing safety profile, consistent with the MEK inhibitor class. The highest-grade treatment-related adverse event (TRAE) was Grade 1 or 2 in 21 of 26 patients (81%) and Grade 3 in four patients (15%); one patient experienced no TRAEs. No Grade 4 or 5 TRAEs were reported. No additional discontinuations were reported since the previous data cutoff.
• Registrational trial: The Company anticipates initiating a registrational trial in the second half of 2027, pending ongoing FDA discussions, and will provide additional details later this year.

Denver, Colorado, Nov. 02, 2026 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced new positive Phase 2 data from the ongoing TUPELO trial of REC-4881, an investigational, oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The new analyses show that most patients had reductions in both the number of larger, higher-risk polyps and in lower GI polyp burden, building on the upper GI results announced on October 15, 2026. Together, these findings support the potential of REC-4881 as an oral therapy to address FAP across the GI tract. Lisa Boardman, M.D., a gastroenterologist and Professor of Medicine at Mayo Clinic, presented the results in a Presidential Plenary at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting in Denver, Colorado.

“People have been doing research in the chemoprevention space in FAP for decades, and at least in the United States, we still don’t have an agent that is FDA approved. We’re still having to send FAP patients for major surgeries and we’re still doing frequent scopes on these patients. The need for effective chemoprevention in FAP is very large, and it’s only going to increase over time as the number of FAP patients continues to increase,” said Bryson Katona, M.D., Ph.D., Director of the GI Cancer Genetics Program, University of Pennsylvania Perelman School of Medicine, and TUPELO study investigator.

“We recently shared data that showed deep, durable reductions in polyps with REC-4881, particularly in the upper GI, where patients with FAP face the greatest risk and the fewest options. Today’s update goes a layer deeper. REC-4881 is reducing the larger polyps that often drive much of the surgery for these patients, across the GI tract from a single oral therapy,” said Najat Khan, Ph.D., President and Chief Executive Officer of Recursion. “This is a lifelong disease with no approved pharmacologic therapies, and REC-4881 is the clearest proof point yet of what we built Recursion to do. Our priority now is to align with the FDA on a registrational path and move with focus and discipline toward a trial in the second half of 2027.”

Latest Data from Phase 2 Trial of REC-4881

Deep reductions in total polyp burden, sustained off treatment

The TUPELO study was designed to study polyp burden reduction after 12 weeks on REC-4881 (4 mg QD) and again after 12 weeks off-treatment. Results show a rapid and durable treatment effect across the GI tract. Trial results have strengthened since the November 2025 data cut, including expanded adult FAP population ages 18 years and older:

• 87% of patients (13 of 15) had a reduction in total polyp burden after 12 weeks of treatment, with a 47% median reduction. One in three patients achieved reductions of 65% or more.
• All patients added since the November 2025 data cut (n=4) had a reduction in total polyp burden, including two patients with 89% and 98% reduction, respectively. At Week 25, after 12 weeks off-treatment, 85% of patients (11 of 13) remained below baseline.
• The persistence of polyp burden reduction below baseline in most patients may allow for dosing flexibility, which could matter in the long-term management of a chronic disease.

“The durability of a reduction in polyp burden is an important metric to understand for any type of chemopreventive agent in FAP. The dream chemopreventive agent for FAP is one that a patient doesn’t have to take lifelong and that potentially could be taken for a shorter amount of time or with an intermittent dosing pattern. Seeing durability over a twelve-week course is certainly encouraging. In longer trials we’ll see exactly how long that durability lasts, but I think it is a very encouraging first sign for this drug,” said Dr. Katona.

Activity across the upper and lower GI tract, including near-clearance

For post-colectomy patients, upper GI disease represents the highest unmet need in FAP, due to risks of bleeding and perforation from polyp removal, high complication rates from surgery, and high cancer risk. When endoscopic management is no longer sufficient to control duodenal disease, patients may require major surgery, including removal of the duodenum. Lower GI disease also remains a concern after colectomy, as polyps can continue to develop in the remaining rectum or ileal pouch, posing an ongoing cancer risk and potential need for additional surgery. REC-4881 has now shown polyp burden reductions in both regions.

Upper GI findings:

• 92% of patients (12 of 13) had reductions in polyp burden after 12 weeks of treatment, with a 55% median reduction. Nearly 1 in 2 patients achieved reductions of ≥65%, and two patients achieved reductions of ≥98%.
• Half (6 of 12) improved by at least one Spigelman stage at Week 13, a widely used system clinicians use to grade duodenal polyposis and decide how often patients need endoscopy and when surgery is recommended.
• 92% (11 of 12) remained below baseline at Week 25, after 12 weeks off-treatment, and 6 of 11 had equal or greater reductions during the off-treatment period than during treatment.

Lower GI findings:

• 9 of 11 patients (82%) with measurable polyp burden at baseline had reductions after 12 weeks of treatment, with a 50% median reduction, and 1 in 3 achieved reductions of 65% or more.
• At Week 25, after 12 weeks off-treatment, 70% of evaluable patients remained below baseline.

Substantial reductions in larger, higher-risk polyps

Polyp size is one of the primary risk factors in FAP. The chance that a polyp contains high-grade dysplasia or cancer increases with polyp size, and clinical guidelines use size to decide which polyps to remove and how often patients need endoscopy. In a new analysis, REC-4881 reduced the number of polyps >5 mm in most patients who had them at baseline:

• Six of eight patients had fewer polyps >5 mm after 12 weeks of treatment, and in four patients the count fell by ≥80%.
• In two patients, more than 90 larger polyps were reduced to a single polyp. In both of those patients, all of the larger polyps were in the upper GI.
• The highest Week 13 responder went from 1,344 mm of total polyp burden to 32 mm, a 98% reduction, and from 96 upper GI polyps >5 mm to one. This is a single patient and is not representative of the overall population.
• Six of the eight patients assessed at Week 25 were below their baseline count after 12 weeks off-treatment. Most of the larger polyps at baseline were in the upper GI.

Note that the study collected polyp counts using >5 mm as the largest size category, which is inclusive of all polyps above this threshold; separate counts for polyps >10 mm were not collected.

No new safety signals observed

MEK1/2 inhibitors are an established class with a well-characterized side-effect profile. Across the 26 safety-evaluable patients dosed at 4 mg (five in Phase 1b and 21 in Phase 2), treatment was well tolerated, with a safety profile consistent with other MEK inhibitors and with previously reported results. No new safety signals were observed as of the data cutoff in the expanded patient population, which includes patients 18 and older.

• The majority of treatment-related adverse events (TRAE) were Grade 1 or 2 (21 of 26 patients, 80.8%). The highest-grade TRAE was Grade 3 in four patients (15.4%), and there were no Grade 4 or 5 TRAEs.
• The most common TRAEs were consistent with MEK1/2 inhibition, including dermatitis acneiform, rash, CPK increase, diarrhea, and asymptomatic LVEF decrease. Adverse events were manageable, and most resolved within 12 weeks off-treatment.
• Four patients discontinued for Grade 1 or 2 TRAEs, with no discontinuations for a Grade 3 event. No additional discontinuations were reported since the previous data cutoff.

Next steps

The Company anticipates initiating a registrational trial in the second half of 2027, pending ongoing FDA discussions, and will provide additional details later this year.

About FAP

FAP is a rare, inherited disease that affects more than 50,000 patients in the US and EU5, with no approved pharmacologic therapies. It is caused by mutations in the APC gene, and without surgery to remove the colon, the lifetime risk of colorectal cancer approaches 100%. Colectomy does not stop the disease, as polyps keep forming in the remaining rectum or ileal pouch and in the upper GI tract, so patients face lifelong endoscopic surveillance, repeated polyp removal and, for some, further major surgery. Based on Company estimates, FAP represents a potential $15 billion opportunity.
Among the approximately 35,000 post-colectomy patients, upper GI disease is the area of greatest unmet need. Nearly all patients develop adenomas in the duodenum, and duodenal or ampullary cancer is a leading cause of cancer-related death after colectomy. The thin duodenal wall raises the risk of bleeding and perforation when these polyps are removed. When endoscopy can no longer control the disease, patients may need major surgery, such as removal of the duodenum or a Whipple procedure, which carries significant morbidity and a long recovery.
Natural History of FAP

To better understand the natural history of FAP and to put the single-arm results of TUPELO in context, the Company collaborated with Amsterdam University Medical Center to analyze a registry of approximately 200 patients with FAP. In 47 patients matched to the original TUPELO eligibility criteria, polyp burden increased over time in both the upper and lower GI. In the 35 patients with upper GI involvement, mean annualized polyp burden increased by 33%. In the 28 patients with lower GI involvement, mean annualized polyp burden increased by 88%. These results help to contextualize the polyp burden reduction observed after 12 weeks of REC-4881 treatment.

REC-4881 Background and Dual Mechanism

REC-4881, a potential first-in-class oral therapy granted FDA Orphan Drug and Fast Track designations, is an allosteric inhibitor of MEK1 and MEK2 designed to address both Wnt/β-catenin initiation and MAPK evolution pathways. The opportunity was identified through unbiased phenotypic screening using Recursion’s AI foundation models, which showed that MEK1/2 inhibition could potentially reverse the cellular effects of APC loss. This dual mechanism differentiates REC-4881 from other single-agent therapies studied in FAP, which have each been directed at a single pathway, and provides the potential to suppress both pathways and reduce polyp burden across the GI tract.

About the TUPELO Trial of REC-4881

REC-4881 is being evaluated in the Phase 1b/2 TUPELO open label study (NCT05552755) assessing its safety, tolerability, pharmacokinetics (PK), and efficacy as a monotherapy in post-colectomy patients aged 18+ years with familial adenomatous polyposis (FAP).

About Recursion

Recursion (NASDAQ: RXRX) is a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need. Enabling its mission is the Recursion OS, an AI-native, end-to-end drug discovery and development platform integrating biology, chemistry, and clinical development into a unified intelligence system. Powered by proprietary multimodal data, purpose-built AI models, and bilingual teams fluent in both science and AI, the Recursion OS is designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting.
Recursion’s platform infrastructure is anchored in Salt Lake City, Utah and Milton Park, Oxfordshire, where its automated biology and chemistry laboratories generate proprietary data at industrial scale. Recursion also maintains offices in New York, Montréal, and London, three global hubs for talent and leadership at the intersection of AI and scientific innovation.

Forward-Looking Statements

This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those regarding the potential efficacy, safety, tolerability, and durability of response of REC-4881; the clinical relevance of the TUPELO trial data and the natural history analysis, and the potential for additional data to confirm such results; the outcome and timing of Recursion’s ongoing discussions with the FDA regarding a registrational path for REC-4881; the design, timing of initiation, and outcomes of a registrational trial of REC-4881, including anticipated initiation in the second half of 2027, and the timing of additional details regarding such trial; the potential for REC-4881 to be a first-in-class therapy for FAP and to address unmet need in FAP; the potential benefits of REC-4881’s Orphan Drug and Fast Track designations; the estimated FAP patient population and market opportunity; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “project,” “seek,” “should,” “target,” “will,” “would,” and similar terms, or the negative of these terms. These statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; the risk that preliminary or interim data from the TUPELO trial, which are based on a limited number of patients, may change as additional data become available or may not be predictive of results in later-stage trials, and that comparisons to natural history data may not be indicative of results in controlled trials; the risk that the FDA may not agree with our proposed registrational path or may require additional data or trials; our ability to leverage and enhance our drug discovery platform; risks related to our development and use of artificial intelligence and machine learning models, including the quality, sufficiency, and integrity of the data on which such models are trained and evolving laws and regulations governing artificial intelligence; our reliance on third parties, including contract research and contract manufacturing organizations, for the conduct of preclinical studies, clinical trials, and manufacturing; competition from other companies pursuing similar technologies or drug candidates; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions and speak only as of the date of this document. Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

Media Contact
media@recursion.com
Investor Contact
investor@recursion.com

CONTACT: Ryan Kelly
Recursion Pharmaceuticals
media@recursion.com

STEINHAUSEN, Switzerland, Nov. 02, 2026 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) today issued a quarterly Fleet Status Report that provides the current activity and contractual status of the Company’s fleet of offshore drilling rigs.

UPDATES
This quarter’s report includes the following updates:

• Deepwater Conqueror –
  • Awarded a two-well contract with an undisclosed operator in Equatorial Guinea.
  • Awarded a five-well contract by an undisclosed operator in the U.S. Gulf.
• Deepwater Proteus –
  • Client exercised one optional well estimated at 60 days.
  • Awarded a ten-well contract by an unnamed operator in the U.S. Gulf.
• Dhirubhai Deepwater KG2 – Announced a two-year binding Letter of Award with ONGC in India.
• Transocean Norge – Awarded a two-well contract with one single-well option by A/S Norske Shell in Norway.
• Transocean Equinox – Client exercised one optional well estimated at 50 days.

In late September, final approval was received from Equinor for the previously announced agreement for three harsh environment semisubmersible rigs in Norway: Transocean Enabler, Transocean Encourage, and Transocean Endurance. The total contract value of approximately $1.0 billion is now included in Transocean’s backlog.

The total aggregate incremental backlog associated with these firm fixtures is approximately $2.0 billion.

As of November 2, 2026, the Company’s total backlog is approximately $8.0 billion.

The report can be accessed on the Company’s website: www.deepwater.com.

ABOUT TRANSOCEAN

Transocean is a leading international provider of offshore contract drilling services for oil and gas wells. The Company specializes in technically demanding sectors of the global offshore drilling business with a particular focus on ultra-deepwater and harsh environment drilling services and operates the highest specification floating offshore drilling fleet in the world.

Transocean owns or has partial ownership interests in and operates a fleet of 27 mobile offshore drilling units, consisting of 20 ultra-deepwater floaters and seven harsh environment floaters.

FORWARD-LOOKING STATEMENTS

The statements described herein that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements could contain words such as “approximately,” “estimated,” or other similar expressions. Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are beyond our control, and in many cases, cannot be predicted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. Factors that could cause actual results to differ materially include, but are not limited to, the level of activity in offshore oil and gas exploration and development, exploration success by producers, operating hazards and delays, risks associated with international operations, actions by customers and other third parties, the fluctuation of current and future prices of oil and gas, the global and regional supply and demand for oil and gas, the intention to scrap certain drilling rigs, the effects of the spread of and mitigation efforts by governments, businesses and individuals related to contagious illnesses, and other factors, including our expectations regarding the timing, completion and anticipated benefits of the proposed business combination with Valaris Limited, an exempted company limited by shares incorporated under the laws of Bermuda, and other risks discussed in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, and in the Company’s other filings with the SEC, which are available free of charge on the SEC’s website at: www.sec.gov. All subsequent written and oral forward-looking statements attributable to the Company or to persons acting on our behalf are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of the particular statement. We expressly disclaim any obligations or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in our expectations or beliefs with regard to the statement or any change in events, conditions or circumstances on which any forward-looking statement is based, except as required by law. All non-GAAP financial measure reconciliations to the most comparative GAAP measure are displayed in quantitative schedules on the Company’s website at www.deepwater.com.

This press release, or referenced documents, do not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and do not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”) or advertising within the meaning of the FinSA. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of Transocean. Investors must rely on their own evaluation of Transocean and its securities, including the merits and risks involved, when making any investment decision involving Transocean securities.

ANALYST CONTACT:
Sarah Davidson
+1 713-232-7217

MEDIA CONTACT:
Kristina Mays
+1 713-232-7734

CEDARHURST, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) — Postal Realty Trust, Inc. (NYSE: PSTL) (the “Company”), a publicly traded REIT focused on acquiring and managing critical logistics infrastructure primarily leased to the US Postal Service (the “USPS”), announced today that its board of directors has approved a quarterly dividend on the Company’s Class A common stock in the amount of $0.245 per share. This represents a 1.0% increase from the third quarter 2025 dividend. The dividend will be payable on November 27, 2026 to stockholders of record as of the close of business on November 13, 2026.

About Postal Realty Trust, Inc.

Postal Realty Trust, Inc. is an internally managed real estate investment trust that owns and manages over 2,400 properties leased primarily to the USPS. More information is available at postalrealtytrust.com.

Forward-Looking and Cautionary Statements

This press release contains “forward-looking statements.” Forward-looking statements include statements that are based on various assumptions (some of which are beyond the Company’s control) and may be identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company’s current expectations and assumptions regarding capital market conditions, the Company’s business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, the Company’s actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the USPS’s terminations or non-renewals of leases, changes in demand for postal services delivered by the USPS, the solvency and financial health of the USPS, competitive, financial market and regulatory conditions, general real estate market conditions, the Company’s competitive environment and other factors set forth under “Risk Factors” in the Company’s filings with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

Contacts:
Steve Bakke
EVP and Chief Financial Officer
Email: Sbakke@postalrealty.com
Phone: (516) 734-0420

Jordan Cooperstein
Senior Vice President of Finance, Capital Markets
Email: Jcooperstein@postalrealty.com
Phone: (516) 295-7820

CHICAGO, Nov. 02, 2026 (GLOBE NEWSWIRE) — XAI Floating Rate & Alternative Income Trust (the “Trust”) has declared its regular monthly distribution of $0.225 per share on the Trust’s common shares (NYSE: XFLT), payable on December 1, 2026, to common shareholders of record as of November 16, 2026, as noted below. The amount of the distribution represents no change from the previous month’s distribution amount of $0.225 per share.

The following dates apply to the declaration:

Ex-Dividend Date	November 16, 2026
Record Date	November 16, 2026
Payable Date	December 1, 2026
Amount	$0.225 per common share
Change from Previous Month	No Change

Common share distributions may be paid from net investment income (regular interest and dividends), capital gains and/or a return of capital. The specific tax characteristics of the distributions will be reported to the Trust’s common shareholders on Form 1099 after the end of the 2026 calendar year. Shareholders should not assume that the source of a distribution from the Trust is net income or profit. For further information regarding the Trust’s distributions, please visit www.xainvestments.com.

The Trust’s net investment income and capital gain can vary significantly over time; however, the Trust seeks to maintain more stable common share monthly distributions over time. The Trust’s investments in CLOs are subject to complex tax rules and the calculation of taxable income attributed to an investment in CLO subordinated notes can be dramatically different from the calculation of income for financial reporting purposes under accounting principles generally accepted in the United States (“U.S. GAAP”), and, as a result, there may be significant differences between the Trust’s GAAP income and its taxable income. The Trust’s final taxable income for the current fiscal year will not be known until the Trust’s tax returns are filed.

As a registered investment company, the Trust is subject to a 4% excise tax that is imposed if the Trust does not distribute to common shareholders by the end of any calendar year at least the sum of (i) 98% of its ordinary income (not taking into account any capital gain or loss) for the calendar year and (ii) 98.2% of its capital gain in excess of its capital loss (adjusted for certain ordinary losses) for a one-year period generally ending on October 31 of the calendar year (unless an election is made to use the Trust’s fiscal year). In certain circumstances, the Trust may elect to retain income or capital gain to the extent that the Board of Trustees, in consultation with Trust management, determines it to be in the interest of shareholders to do so.

The common share distributions paid by the Trust for any particular period may be more than the amount of net investment income from that period. As a result, all or a portion of a distribution may be a return of capital, which is in effect a partial return of the amount a common shareholder invested in the Trust, up to the amount of the common shareholder’s tax basis in their common shares, which would reduce such tax basis. Although a return of capital may not be taxable, it will generally increase the common shareholder’s potential gain, or reduce the common shareholder’s potential loss, on any subsequent sale or other disposition of common shares.

The distribution shall be paid on the Payable Date unless the payment of such distribution is deferred by the Board of Trustees upon a determination that such deferral is required in order to comply with applicable law to ensure that the Trust remains solvent and able to pay its debts as they become due and continue as a going concern, or to comply with the applicable terms or financial covenants of the Trust’s senior securities.

Future common share distributions will be made if and when declared by the Trust’s Board of Trustees, based on consideration of a number of factors, including the Trust’s continued compliance with terms and financial covenants of its senior securities, the Trust’s net investment income, financial performance and available cash. There can be no assurance that the amount or timing of common share distributions in the future will be equal or similar to that described herein or that the Board of Trustees will not decide to suspend or discontinue the payment of common share distributions in the future.

The investment objective of the Trust is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle. The Trust seeks to achieve its investment objective by investing in a dynamically managed portfolio of opportunities primarily within the private credit markets. Under normal market conditions, the Trust will invest at least 80% of its Managed Assets in floating rate credit instruments and other structured credit investments. There can be no assurance that the Trust will achieve its investment objective.

The Trust’s common shares are traded on the New York Stock Exchange under the symbol “XFLT”.

About XA Investments

XA Investments LLC (“XA Investments”) is a Chicago-based firm founded by XMS Capital Partners in 2016. XA Investments serves as the investment adviser for two listed closed-end funds, an interval fund, and a tender offer fund. The listed closed-end funds, the XAI Floating Rate & Alternative Income Trust and XAI Madison Equity Premium Income Fund both trade on the New York Stock Exchange and the interval fund and tender offer fund, XAI CLO & Income Opportunities Fund and Evanston Multi-Alpha Fund are both available via direct subscription and through select broker/dealers and wealth management platforms.

In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XA Investments offers custom product build and consulting services, including product development and market research, marketing and fund management.

XA Investments believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. XA Investments provides individual investors with access to institutional-caliber alternative managers. For more information, please visit www.xainvestments.com.

About XMS Capital Partners
XMS Capital Partners, LLC, established in 2006, is a global, independent, financial services firm providing M&A, corporate advisory and asset management services to clients. It has offices in Chicago, Boston and London. For more information, please visit www.xmscapital.com.

About Rockford Tower Asset Management
Rockford Tower Asset Management, L.L.C. is a wholly owned subsidiary of King Street Capital Management, L.P. (“King Street”) and an affiliate of Rockford Tower Capital Management (“Rockford Tower”). Rockford Tower, King Street’s dedicated CLO, CBO and SMA platform, was formed in 2017. Rockford Tower has over $14.7 billion of assets under management as of September 30, 2026, across 19 U.S. CLOs and 10 European CLOs, one CBO transaction and one SMA. In addition, Rockford Tower has traded over $99 billion of loans as of December 31, 2025.

About King Street Capital Management
King Street is a global alternative investment firm founded in 1995 that manages $30.9 billion in assets across public and private markets. The firm marries rigorous fundamental research with tactical trading and differentiated sourcing capabilities to identify investment opportunities across asset classes, up and down the capital structure. For more information, please visit www.kingstreet.com.

XA Investments does not provide tax advice; please consult a professional tax advisor regarding your specific tax situation. Income may be subject to state and local taxes, as well as the federal alternative minimum tax.

Investors should consider the investment objectives and policies, risk considerations, charges and expenses of the Trust carefully before investing. For more information on the Trust, please visit the Trust’s webpage at www.xainvestments.com.  

This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction.

NOT FDIC INSURED	NO BANK GUARANTEE	MAY LOSE VALUE

Paralel Distributors, LLC – Distributor

Media Contact:

Kimberly Flynn, President
XA Investments LLC
Phone:  888-903-3358
Email: KFlynn@XAInvestments.com
www.xainvestments.com

NORTHFIELD, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) — Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that Jim Boyle, chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 3:30pm Greenwich Mean Time (GMT).

A webcast of the presentation will be available on the Events page of Medline’s Investor Relations website at ir.medline.com. A replay of the webcast will be available on Medline’s Investor Relations website for 120 days following the event.

About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Illinois, the company employs more than 45,000 people worldwide and operates in more than 100 countries. To learn more about how Medline makes healthcare run better, visit www.medline.com.
  
Contacts
Investor Relations:
Karen King
Global Head of Investor Relations

Patrick Flaherty
Director, Investor Relations

(847) 247-7222
IR@medline.com

Media Relations:
Ben Fox
Vice President, Corporate Communications
(224) 327-9999
MedlineMediaRelations@medline.com

Source: Medline Inc.

SUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) — Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the appointment of Aaron Martin, President of Insurance at Humana, to its board of directors, effective January 1, 2027.

“Aaron has spent his career building and scaling healthcare technology at the point where payers, providers, and patients converge – a perspective that will sharpen our board’s thinking as we further expand access to minimally invasive care globally,” said Intuitive CEO Dave Rosa. “His combination of digital innovation expertise, health system leadership, and large-scale insurance operations experience will deepen our ability to reach more patients with the best care.”

In his role at Humana, Martin holds broad responsibility for strategy, growth, operations, and financial performance across Humana’s insurance portfolio and serves on the Humana Enterprise Leadership Team, reporting to the CEO. Prior to Humana, Martin spent almost four years at Amazon as Vice President of Healthcare, where he launched Amazon Clinic – the company’s first message and video-based telehealth platform – and built Amazon’s Health Conditions Programs in partnership with leading digital health companies. He also led brand and performance marketing and strategic partnerships for Amazon Health Services.

Before Amazon, Martin served as Executive Vice President and Chief Digital Officer at Providence St. Joseph Health, a $26 billion not-for-profit health system, where he led the consumer-facing digital business and founded and served as Managing General Partner of Providence Ventures, a $300 million corporate venture fund with 27 portfolio companies. He has also served as a board member for organizations including Kyruus, Wildflower Health, Xealth, DexCare, AVIA, and Presbyterian Health System.

Martin holds a Bachelor of Arts in Business & Economics and Music Performance from Austin College and an MBA in Finance and Healthcare Management from the Wharton School of the University of Pennsylvania.

“Intuitive has differentiated its platforms by leveraging the power of technology to enhance patient care and improve outcomes, and I am honored to join the board at such an exciting moment in the company’s journey,” said Martin. “I look forward to contributing to expanding access to minimally invasive care for more patients worldwide.”

With Martin’s addition, Intuitive’s board of directors will expand from 10 to 11 members.

Contact Information:
Media.inquiries@intusurg.com

About Intuitive

Intuitive (NASDAQ: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.

Forward-Looking Statements

This press release contains forward-looking statements which relate to expectations concerning matters that are not historical facts. Statements using words such as “anticipates,” “expects,” “intends,” “may,” “will,” “can,” “could,” “should,” “would,” and similar words and expressions are intended to identify forward-looking statements. It includes a forward-looking statement regarding the anticipated effective date of Martin’s appointment to the board of directors. The appointment is subject to Martin’s continued willingness and ability to serve, and actual results may differ. It also includes statements about expanding access to minimally invasive care and our ability to reach more patients. These forward-looking statements should be considered in light of various important factors and involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Intuitive to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release and which are based on current expectations and are subject to risks, uncertainties, and assumptions that are difficult to predict. Intuitive undertakes no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

• Record First Quarter Revenue Increased 51% From Prior Year, Exceeding Guidance Range

BANGKOK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced its financial results for its first fiscal quarter ended September 25, 2026.

Seamus Grady, Chairman and Chief Executive Officer of Fabrinet, said, “Fiscal year 2027 is off to an excellent start with record revenue and non-GAAP earnings per share that were well above our guidance ranges. Broad-based demand across multiple significant programs drove these results, with new product ramps further supporting our growth. We enter the second quarter with exceptional momentum that makes us confident that we can deliver another strong performance.”

First Quarter Fiscal Year 2027 Financial Highlights

GAAP Results

• Revenue for the first quarter of fiscal year 2027 was $1,474.5 million, compared to $978.1 million for the first quarter of fiscal year 2026.
• GAAP net income for the first quarter of fiscal year 2027 was $103.5 million, compared to $95.9 million for the first quarter of fiscal year 2026.
• GAAP net income per diluted share for the first quarter of fiscal year 2027 was $2.86, compared to $2.66 for the first quarter of fiscal year 2026.

Non-GAAP Results

• Non-GAAP net income for the first quarter of fiscal year 2027 was $157.4 million, compared to $105.3 million for the first quarter of fiscal year 2026.
• Non-GAAP net income per diluted share for the first quarter of fiscal year 2027 was $4.34, compared to $2.92 for the first quarter of fiscal year 2026.

Share Repurchase Program Expanded

Fabrinet also announced that its Board of Directors has approved an expansion of its share repurchase program, authorizing the repurchase of up to an additional $103.0 million of Fabrinet’s ordinary shares. The addition brings the aggregate authorization under Fabrinet’s existing share repurchase program to $637.3 million.

Business Outlook

Based on information available as of November 2, 2026, Fabrinet is issuing guidance for its second fiscal quarter ending December 25, 2026, as follows:

• Fabrinet expects second quarter revenue to be in the range of $1.6 billion to $1.65 billion.
• GAAP net income per diluted share is expected to be in the range of $3.81 to $3.96, based on approximately 36.2 million fully diluted shares outstanding.
• Non-GAAP net income per diluted share is expected to be in the range of $4.77 to $4.92, based on approximately 36.2 million fully diluted shares outstanding. 

Guidance for non-GAAP net income per diluted share excludes share-based compensation expenses and certain non-recurring items. A reconciliation of non-GAAP net income per diluted share to the corresponding GAAP measure is available at the end of this press release.

Conference Call Information

What:		Fabrinet First Quarter Fiscal Year 2027 Financial Results Call
When:		November 2, 2026
Time:		5:00 p.m. ET
Live Call and Replay:		https://investor.fabrinet.com/events-and-presentations/events

A recorded version of this webcast will be available approximately two hours after the call and accessible at http://investor.fabrinet.com. The webcast will be archived on Fabrinet’s website for a period of one year.

About Fabrinet

Fabrinet is a leading provider of advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and subsystems, automotive components, medical devices, industrial lasers and sensors. Fabrinet offers a broad range of advanced optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, advanced packaging, integration, final assembly and testing. Fabrinet focuses on production of high complexity products in any mix and any volume. Fabrinet maintains engineering and manufacturing resources and facilities in Thailand, the United States of America, the People’s Republic of China, and Israel. For more information visit: www.fabrinet.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include (1) our statement relating to our confidence that we will be able to deliver a strong performance in the second quarter of fiscal year 2027 and (2) all of the statements under the “Business Outlook” section regarding our expected revenue, GAAP and non-GAAP net income per share, and fully diluted shares outstanding for the second quarter of fiscal year 2027. These forward-looking statements involve risks and uncertainties, and actual results could vary materially from these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: changes in general economic conditions, either globally or in our markets, and the risk of recession or an economic downturn; disruption to our supply chain, which could increase our costs and affect our ability to procure parts and materials; less customer demand for our products and services than forecasted; less growth in the data center, communications infrastructure, automotive, industrial and other markets than we forecast; difficulties expanding into additional markets, such as the semiconductor processing, biotechnology, metrology and materials processing markets; increased competition in the optical manufacturing services markets; difficulties in delivering products and services that compete effectively from a price and performance perspective; our reliance on a small number of customers and suppliers; difficulties in managing our operating costs; difficulties in managing and operating our business across multiple countries (including Thailand, the People’s Republic of China, Israel and the U.S.); and other important factors as described in reports and documents we file from time to time with the Securities and Exchange Commission (SEC), including the factors described under the section captioned “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on August 18, 2026. We disclaim any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Non-GAAP Financial Measures

In addition to reporting financial results in accordance with GAAP, we provide investors with certain non-GAAP financial measures. These non-GAAP financial measures are in addition to, and not a substitute for or superior to, measures of financial performance prepared in accordance with GAAP. We believe these non-GAAP financial measures provide investors with useful supplemental information to: (1) measure company performance against historical results, (2) facilitate comparisons to our competitors’ operating results, and (3) allow greater transparency with respect to information used by management in making financial and operational decisions. In addition, we use some of these non-GAAP financial measures to measure company performance for the purposes of determining employee incentive plan compensation.

Non-GAAP gross profit, non-GAAP operating profit, non-GAAP net income and non-GAAP net income per diluted share exclude: share-based compensation expenses; severance payment and others; restructuring and other related costs; legal and litigation costs; non-marketable equity securities revaluation; and charges arising from the implementation or application of the OECD Pillar Two global minimum tax framework, including charges resulting from changes in implementing regulations, administrative guidance or related governmental measures. We have excluded these items in order to enhance investors’ understanding of our underlying operations.

Non-GAAP free cash flow is net cash provided by (used in) operating activities, minus capital expenditures (purchase of property, plant and equipment). We use free cash flow to measure our ability to generate additional cash from our business operations.

There are a number of limitations related to the use of these non-GAAP financial measures versus their nearest GAAP equivalents. For example, other companies may calculate non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. We urge you to review the reconciliations of our non-GAAP financial measures to the most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Investor Contact:
Garo Toomajanian
ir@fabrinet.com

FABRINET CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands of U.S. dollars, except share data and par value)	September 25, 2026				June 26, 2026
	(unaudited)
Assets
Current assets
Cash and cash equivalents	$	392,326			$	346,711
Short-term investments		363,427				528,344
Trade accounts receivable, net of allowance for expected credit losses of $1,042 and $1,050, respectively		1,161,412				1,017,933
Inventories		1,193,094				1,021,235
Prepaid expenses		48,879				49,915
Other current assets		262,233				195,571
Total current assets		3,421,371				3,159,709
Non-current assets
Long-term restricted cash		918				704
Property, plant and equipment, net		778,230				615,067
Intangibles, net		2,278				2,458
Operating right-of-use assets		3,613				3,974
Deferred tax assets		19,429				19,229
Non-marketable equity securities		67,647				89,103
Other non-current assets		24,150				20,717
Total non-current assets		896,265				751,252
Total Assets	$	4,317,636			$	3,910,961
Liabilities and Shareholders’ Equity
Current liabilities
Long-term borrowings, current portion, net	$	11,211			$	—
Trade accounts payable		1,269,073				1,005,761
Fixed assets payable		96,037				86,018
Operating lease liabilities, current portion		926				1,189
Income tax payable		85,507				63,469
Accrued payroll, bonus and related expenses		32,208				29,850
Accrued expenses		36,676				56,549
Severance liabilities, current portion		2,315				2,319
Other payables		143,640				157,470
Total current liabilities		1,677,593				1,402,625
Non-current liabilities
Long-term borrowings, non-current portion, net		63,528				—
Deferred tax liability		2,519				1,654
Operating lease liability, non-current portion		2,655				2,824
Severance liabilities		32,843				31,776
Other non-current liabilities		22,444				17,826
Total non-current liabilities		123,989				54,080
Total Liabilities		1,801,582				1,456,705
Shareholders’ equity
Preferred shares (5,000,000 shares authorized, $0.01 par value; no shares issued and outstanding as of September 25, 2026 and June 26, 2026)		—				—
Ordinary shares (500,000,000 shares authorized, $0.01 par value; 39,797,868 shares and 39,722,708 shares issued as of September 25, 2026 and June 26, 2026, respectively; and 35,833,303 shares and 35,834,864 shares outstanding as of September 25, 2026 and June 26, 2026, respectively)		398				397
Additional paid-in capital		241,623				251,854
Less: Treasury shares (3,964,565 shares and 3,887,844 shares as of September 25, 2026 and June 26, 2026, respectively)		(394,430	)			(365,287	)
Accumulated other comprehensive income (loss)		(1,358	)			968
Retained earnings		2,669,821				2,566,324
Total Shareholders’ Equity		2,516,054				2,454,256
Total Liabilities and Shareholders’ Equity	$	4,317,636			$	3,910,961

FABRINET CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED)
		Three Months Ended
(in thousands of U.S. dollars, except per share data)		September 25, 2026				September 26, 2025
Revenues		$	1,474,459			$	978,128
Cost of revenues			(1,300,661	)			(861,689	)
Gross profit			173,798				116,439
Selling, general and administrative expenses			(26,744	)			(22,246	)
Restructuring and other related costs			(1,049	)			—
Operating income			146,005				94,193
Interest income			5,539				9,417
Interest expense			(231	)			—
Foreign exchange gain (loss), net			(220	)			(2,060	)
Other income (expense), net			(21,592	)			(122	)
Income before income taxes			129,501				101,428
Income tax expense			(26,004	)			(5,502	)
Net income			103,497				95,926
Other comprehensive income (loss), net of tax:
Change in net unrealized gain (loss) on available-for-sale securities			(4,145	)			(811	)
Change in net unrealized gain (loss) on derivative instruments			1,812				(2,062	)
Change in foreign currency translation adjustment			7				(89	)
Total other comprehensive income (loss), net of tax			(2,326	)			(2,962	)
Net comprehensive income		$	101,171			$	92,964
Earnings per share
Basic		$	2.89			$	2.68
Diluted		$	2.86			$	2.66
Weighted-average number of ordinary shares outstanding (in thousands of shares)
Basic			35,866				35,773
Diluted			36,233				36,097

FABRINET CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
	Three Months Ended
(in thousands of U.S. dollars)	September 25, 2026				September 26, 2025
Cash flows from operating activities
Net income for the period	$	103,497			$	95,926
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization		21,700				14,860
(Gain) loss on disposal of property, plant and equipment and intangibles		(124	)			(6	)
(Gain) loss on non-marketable equity securities		21,456				—
(Gain) loss from sales and maturities of available-for-sale securities		(73	)			—
Amortization of discount (premium) of short-term investments		(707	)			(1,222	)
Inventory obsolescence impairment		6,333				2,290
(Reversal of) allowance for expected credit losses		(8	)			(45	)
Unrealized loss (gain) on exchange rate and fair value of foreign currency forward contracts		4,095				461
Share-based compensation		11,225				9,071
Customer warrant		2,455				286
Deferred income tax expense (benefit)		608				(106	)
Other non-cash expenses		135				66
Changes in operating assets and liabilities
Trade accounts receivable		(143,301	)			51,821
Inventories		(178,192	)			(143,469	)
Other current assets and non-current assets		(81,171	)			(13,579	)
Trade accounts payable		262,069				59,508
Income tax payable		22,038				2,993
Accrued expenses		(19,791	)			(2,539	)
Other payables		(15,425	)			23,284
Severance liabilities		1,112				826
Other current liabilities and non-current liabilities		3,356				2,142
Net cash provided by operating activities		21,287				102,568
Cash flows from investing activities
Purchase of short-term investments		(996	)			(110,329	)
Proceeds from sales of short-term investments		111,848				—
Proceeds from maturities of short-term investments		50,700				74,789
Purchase of property, plant and equipment		(158,698	)			(45,266	)
Purchase of intangibles		(239	)			(169	)
Proceeds from disposal of property, plant and equipment		150				15
Net cash provided by (used in) investing activities		2,765				(80,960	)
Cash flows from financing activities
Proceeds from long-term borrowings		74,828				—
Repurchase of ordinary shares		(29,143	)			(268	)
Withholding tax related to net share settlement of restricted share units		(23,910	)			(22,697	)
Net cash provided by (used in) financing activities		21,775				(22,965	)
Net increase (decrease) in cash, cash equivalents and restricted cash	$	45,827			$	(1,357	)
Movement in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at the beginning of period	$	347,415			$	306,425
Increase (decrease) in cash, cash equivalents and restricted cash		45,827				(1,357	)
Effect of exchange rate on cash, cash equivalents and restricted cash		2				(67	)
Cash, cash equivalents and restricted cash at the end of period	$	393,244			$	305,001
Non-cash investing and financing activities
Construction, software and equipment-related payables	$	96,037			$	50,941

FABRINET CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:
	As of
(in thousands of U.S. dollars)	September 25, 2026				September 26, 2025
Cash and cash equivalents	$	392,326			$	305,001
Restricted cash		918				—
Cash, cash equivalents and restricted cash	$	393,244			$	305,001

FABRINET RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES (UNAUDITED)
Reconciliation of GAAP Gross Profit and GAAP Gross Margin to Non-GAAP Gross Profit and Non-GAAP Gross Margin
		Three Months Ended
(in thousands of U.S. dollars)		September 25, 2026							September 26, 2025
Revenues		$	1,474,459						$	978,128
Gross profit (GAAP)		$	173,798			11.8	%		$	116,439			11.9	%
Share-based compensation expenses			4,203							3,519
Gross profit (Non-GAAP)		$	178,001			12.1	%		$	119,958			12.3	%

Reconciliation of GAAP Operating Profit and GAAP Operating Margin to Non-GAAP Operating Profit and Non-GAAP Operating Margin
		Three Months Ended
(in thousands of U.S. dollars)		September 25, 2026							September 26, 2025
Revenues		$	1,474,459						$	978,128
Operating profit (GAAP)		$	146,005			9.9	%		$	94,193			9.6	%
Share-based compensation expenses			11,225							9,071
Restructuring and other related costs			1,049							—
Severance payment and others			158							72
Legal and litigation costs			99							256
Operating profit (Non-GAAP)		$	158,536			10.8	%		$	103,592			10.6	%

FABRINET RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES (UNAUDITED)
Reconciliation of GAAP Net Income and EPS to Non-GAAP Net Income and EPS
		Three Months Ended
		September 25, 2026								September 26, 2025
(in thousands of U.S. dollars, except per share data)		Net income				Diluted EPS				Net income				Diluted EPS
GAAP measures		$	103,497			$	2.86			$	95,926			$	2.66
Items reconciling GAAP net income & EPS to non-GAAP net income & EPS:
Related to cost of revenues:
Share-based compensation expenses			4,203				0.12				3,519				0.10
Total related to cost of revenues			4,203				0.12				3,519				0.10
Related to selling, general and administrative expenses:
Share-based compensation expenses			7,022				0.19				5,552				0.15
Legal and litigation costs			99				0.00				256				0.01
Severance payment and others			158				0.00				72				0.00
Total related to selling, general and administrative expenses			7,279				0.19				5,880				0.16
Related to restructuring and other related costs:
Restructuring and other related costs			1,049				0.03				—				—
Total related to restructuring and other related costs			1,049				0.03				—				—
Related to other income and expense:
Non-marketable equity securities revaluation			21,456				0.59				—				—
Total related to other income and expense			21,456				0.59				—				—
Related to income tax (benefit) expense
Tax provision related to Pillar Two			19,885				0.55				—				—
Total related to income tax (benefit) expense			19,885				0.55				—				—
Total related to net income & EPS			53,872				1.48				9,399				0.26
Non-GAAP measures		$	157,369			$	4.34			$	105,325			$	2.92
Shares used in computing diluted net income per share (in thousands of shares)
GAAP diluted shares							36,233								36,097
Non-GAAP diluted shares							36,233								36,097

FABRINET RECONCILIATION OF NET CASH PROVIDED BY OPERATING ACTIVITIES TO FREE CASH FLOW (UNAUDITED)
(in thousands of U.S. dollars)		Three Months Ended
		September 25, 2026				September 26, 2025
Net cash provided by operating activities		$	21,287			$	102,568
Less: Purchase of property, plant and equipment			(158,698	)			(45,266	)
Non-GAAP free cash flow		$	(137,411	)		$	57,302

FABRINET GUIDANCE FOR QUARTER ENDING DECEMBER 25, 2026 RECONCILIATION OF GAAP MEASURES TO NON-GAAP MEASURES
	Diluted EPS
GAAP net income per diluted share	$3.81 to $3.96
Related to cost of revenues:
Share-based compensation expenses	0.11
Total related to cost of revenues	0.11
Related to selling, general and administrative expenses:
Share-based compensation expenses	0.25
Total related to selling, general and administrative expenses	0.25
Related to income tax (benefit) expense:
Tax provision related to Pillar Two	0.60
Total related to income tax (benefit) expense	0.60
Total related to net income & EPS	0.96
Non-GAAP net income per diluted share	$4.77 to $4.92

$0.4714 per unit distribution declared payable on December 1, 2026

HOUSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Westlake Chemical Partners GP LLC, the general partner of Westlake Chemical Partners LP (the “Partnership”) (NYSE:WLKP), has declared a distribution of $0.4714 per unit. This is the 49th quarterly distribution announced by the Partnership since its initial public offering. The distribution will be payable on December 1, 2026, to unit holders of record on November 13, 2026.

This release is intended to be a qualified notice under Treasury Regulation Section 1.1446-4(b). Brokers and nominees should treat one hundred percent (100.0%) of the Partnership’s distributions to non-U.S. investors as being attributable to income that is effectively connected with a United States trade or business. Accordingly, the Partnership’s distributions to non-U.S. investors are subject to federal income tax withholding at the highest applicable effective tax rate.

About Westlake Chemical Partners LP

Westlake Chemical Partners is a limited partnership formed by Westlake Corporation to operate, acquire and develop ethylene production facilities and other qualified assets. Headquartered in Houston, the Partnership owns a 22.8% interest in Westlake Chemical OpCo LP. Westlake Chemical OpCo LP’s assets include three facilities in Calvert City, Kentucky, and Lake Charles, Louisiana which process ethane and propane into ethylene, and an ethylene pipeline. For more information about Westlake Chemical Partners LP, please visit http://www.wlkpartners.com.

Contacts

Media Inquiries:
Westlake Corp.
Ben Ederington, 1-713-585-2900

or

Investor Inquiries:
Westlake Corp.
Jeff Holy, 1-713-585-2900

CHICAGO, Nov. 02, 2026 (GLOBE NEWSWIRE) — XAI Madison Equity Premium Income Fund (the “Fund”) has declared its regular monthly distribution of $0.060 per share on the Fund’s common shares (NYSE: MCN), payable on December 1, 2026, to common shareholders of record as of November 16, 2026, as noted below. The amount of the distribution represents no change from the previous month’s distribution amount of $0.060 per share.

The following dates apply to the declaration:

Ex-Dividend Date	November 16, 2026
Record Date	November 16, 2026
Payable Date	December 1, 2026
Amount	$0.060 per share
Change from Previous Month	No Change

Common share distributions may be paid from net investment income (regular interest and dividends), capital gains and/or a return of capital. The specific tax characteristics of the distributions will be reported to the Fund’s common shareholders on Form 1099 after the end of the 2026 calendar year. Shareholders should not assume that the source of a distribution from the Fund is net income or profit. For further information regarding the Fund’s distributions, please visit www.xainvestments.com.

The Fund’s net investment income and capital gain can vary significantly over time; however, the Fund seeks to maintain more stable common share quarterly distributions over time. The Fund’s final taxable income for the current fiscal year will not be known until the Fund’s tax returns are filed.

As a registered investment company, the Fund is subject to a 4% excise tax that is imposed if the Fund does not distribute to common shareholders by the end of any calendar year at least the sum of (i) 98% of its ordinary income (not taking into account any capital gain or loss) for the calendar year and (ii) 98.2% of its capital gain in excess of its capital loss (adjusted for certain ordinary losses) for a one-year period generally ending on December 31 of the calendar year (unless an election is made to use the Fund’s fiscal year). In certain circumstances, the Fund may elect to retain income or capital gain to the extent that the Board of Trustees, in consultation with Fund management, determines it to be in the interest of shareholders to do so.

The common share distributions paid by the Fund for any particular period may be more than the amount of net investment income from that period. As a result, all or a portion of a distribution may be a return of capital, which is in effect a partial return of the amount a common shareholder invested in the Fund, up to the amount of the common shareholder’s tax basis in their common shares, which would reduce such tax basis. Although a return of capital may not be taxable, it will generally increase the common shareholder’s potential gain, or reduce the common shareholder’s potential loss, on any subsequent sale or other disposition of common shares.

Future common share distributions will be made if and when declared by the Fund’s Board of Trustees, after the evaluation of several factors, including the Fund’s net investment income, financial performance and available cash. There can be no assurance that the amount or timing of common share distributions in the future will be equal or similar to that described herein or that the Board of Trustees will not decide to suspend or discontinue the payment of common share distributions in the future.

The Fund’s objective is to achieve a high level of current income and current capital gains, with long-term capital appreciation as a secondary objective. The Fund intends to pursue its objective by investing in a portfolio of common stocks and utilizing an option strategy, primarily by writing (selling) covered call options on a substantial portion of the common stocks in the portfolio in order to generate current income and gains from option writing premiums and, to a lesser extent, from dividends. Market action can impact dividend issuance as the Fund’s total assets affect the Fund’s future dividend prospects. The Fund provides additional information on its website at www.xainvestments.com.

About XA Investments

XA Investments LLC (“XA Investments”) is a Chicago-based firm founded by XMS Capital Partners in 2016. XA Investments serves as the investment adviser for two listed closed-end funds, an interval fund, and a tender offer fund. The listed closed-end funds, the XAI Floating Rate & Alternative Income Trust and XAI Madison Equity Premium Income Fund both trade on the New York Stock Exchange and the interval fund and tender offer fund, XAI CLO & Income Opportunities Fund and Evanston Multi-Alpha Fund are both available via direct subscription and through select broker/dealers and wealth management platforms.

In addition to investment advisory services, the firm also provides investment fund structuring and consulting services focused on registered closed-end funds to meet institutional client needs. XA Investments offers custom product build and consulting services, including product development and market research, marketing and fund management.

XA Investments believes that the investing public can benefit from new vehicles to access a broad range of alternative investment strategies and managers. XA Investments provides individual investors with access to institutional-caliber alternative managers. For more information, please visit www.xainvestments.com.

About XMS Capital Partners

XMS Capital Partners, LLC, established in 2006, is a global, independent, financial services firm providing M&A, corporate advisory and asset management services to clients. It has offices in Chicago, Boston and London. For more information, please visit www.xmscapital.com.

About Madison Investments

Madison Investments is an independent investment management firm based in Madison, WI. The firm was founded in 1974, has approximately $28.6 billion in assets under management as of September 30, 2026, and is recognized as one of the nation’s top investment firms. Madison offers domestic fixed income, U.S. and international equity, covered call, multi-asset, insurance and credit union investment management strategies. For more information, please visit www.madisoninvestments.com.

Madison and/or Madison Investments is the unifying tradename of Madison Investment Holdings, Inc., Madison Asset Management, LLC, and Madison Investment Advisors, LLC. Madison Funds are distributed by MFD Distributor, LLC. Madison is registered as an investment adviser with the U.S. Securities and Exchange Commission. MFD Distributor, LLC is registered with the U.S. Securities and Exchange Commission as a broker-dealer and is a member firm of the Financial Industry Regulatory Authority www.finra.org.

XA Investments does not provide tax advice; please consult a professional tax advisor regarding your specific tax situation. Income may be subject to state and local taxes, as well as the federal alternative minimum tax.

Investors should consider the investment objectives and policies, risk considerations, charges and expenses of the Fund carefully before investing. For more information on the Fund, please visit the Fund’s webpage at www.xainvestments.com.

This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction.

NOT FDIC INSURED		NO BANK GUARANTEE		MAY LOSE VALUE

Media Contact: 

Kimberly Flynn, President
XA Investments LLC
Phone: 888-903-3358
Email: KFlynn@XAInvestments.com
www.xainvestments.com

– 277,117 Square Feet, 100% Leased to Seven Tenants –

– Upon Closing Will Bring 2026 Acquisition Total to Over $102 Million –

GREAT NECK, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) — One Liberty Properties, Inc. (NYSE: OLP), a real estate investment trust focused on the ownership of industrial properties, today announced it has entered into a contract to acquire a four-building industrial portfolio totaling 277,117 square feet on approximately 25 acres in the Milwaukee, Wisconsin MSA, at a price of $34 million.

The portfolio is 100% leased to seven tenants and generates aggregate annual base rent of approximately $2.3 million, with contractual annual rent increases ranging from approximately 2% to 4% and a weighted average remaining lease term of approximately six years. The tenants span a range of industries, including fabrication, distribution, commercial printing and healthcare services.

The purchase price will be funded with available cash and a mortgage. One Liberty expects to obtain of $20.6 million mortgage that will mature in 2031, bearing a fixed interest rate of 6.36%. The transaction is expected to close in the fourth quarter of 2026.

Patrick J. Callan, Jr., President and Chief Executive Officer of One Liberty, commented, “This acquisition marks another important step in One Liberty’s evolution to an industrial-focused portfolio. It adds scale in a tight industrial submarket where limited available land and steady demand from manufacturers and distributors keep vacancy relatively low. The buildings are leased to a diverse group of operating businesses, and with in-place rents below market, we see room to grow cash flow as leases roll over time.”

The properties are located west of downtown Milwaukee with access to Interstates 43 and 94, in the Waukesha County industrial submarket, which comprises approximately 64 million square feet and is less than 2% vacant. Milwaukee ranks second among major U.S. metros in the share of its workforce employed in manufacturing.

Forward Looking Statement:

Certain information contained in this press release, together with other statements and information publicly disseminated by One Liberty Properties, Inc. is forward looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provision for forward looking statements contained in the Private Securities Litigation Reform Act of 1995 and include this statement for the purpose of complying with these safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe One Liberty’s future plans, strategies and expectations, are generally identifiable by use of the words “may,” “will,” “could,” “believe,” “expect,” “intend,” “anticipate,” “estimate,” “project,” or similar expressions or variations thereof. Information regarding important factors that could cause actual outcomes or other events to differ materially from any such forward-looking statements appear in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the reports filed with the Securities and Exchange Commission thereafter; in particular, the sections of such reports entitled “Cautionary Note Regarding Forward Looking Statements”, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, included therein. In addition, estimates of rental income and base rent exclude any related variable rent and the adjustments required by GAAP to present rental income; anticipated property purchases, sales, financings and/or refinancings may not be completed during the period or on the terms indicated, or at all; estimates of net proceeds and gains from property sales and financings/refinancings are subject to adjustment, among other things, because actual closing costs (including the amounts, if any, required to pay-off mortgage debt on properties being sold) may differ from the estimated costs; anticipated rent increases, including those tied to filling of vacancies or as a result of market-to-market opportunities (i.e., renewing leased premises or leasing vacant premises at higher rental rates) may not be realized; and amounts presented in this press release and the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2026 may differ from one another due to rounding. You should not rely on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could materially affect the Company’s results of operations, financial condition, cash flows, performance or future achievements or events.

About One Liberty Properties:

One Liberty, organized in Maryland in 1982, is an industrial-focused real estate investment trust. The Company owns and operates a geographically diversified portfolio consisting primarily of industrial properties across the United States. Additional financial and descriptive information on One Liberty, its operations and its portfolio, is available on its website at: http://1liberty.com.  Interested parties are encouraged to review One Liberty’s Annual Report on Form 10-K and the other reports it files with the Securities and Exchange Commission for additional information.

Contact:
One Liberty Properties
Investor Relations
Phone: (516) 466-3100
www.1liberty.com